Rituximab used in three cases with relapsed non‑Hodgkin's lymphoma

Elli,Murat; Yilmaz,Sema; Aydin,Ramazan; Murat,Sadriye; Bilgici,Meltem  Ceyhan; Dagdemir,Ayhan

doi:10.3892/mco.2013.88

Rituximab used in three cases with relapsed non‑Hodgkin's lymphoma

Authors:
- Murat Elli
- Sema Yilmaz
- Ramazan Aydin
- Sadriye Murat
- Meltem Ceyhan Bilgici
- Ayhan Dagdemir
View Affiliations

Affiliations: Department of Pediatric Hematology/Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey, Department of Radiology, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey, Department of Pediatrics, Ondokuz Mayıs University, Faculty of Medicine, Samsun 55220, Turkey
Published online on: March 5, 2013 https://doi.org/10.3892/mco.2013.88
Pages: 550-552

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Relapsed or refractory B‑cell non‑Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been used to improve survival rates in children with relapsed or refractory B-NHL. CD20 is expressed in >98% of childhood B-NHL and a chimeric anti‑CD20 monoclonal antibody, rituximab, is increasingly being used at relapse. The aim of the present study was to determine the efficacy of rituximab on relapsed B-NHL. Three B-NHL cases were treated successfully with a combination of intensive chemotherapy protocol plus rituximab.

View Figures

View References

1.	Bilić E, Femenić R, Konja J, et al: CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol. 34:171–175. 2010.PubMed/NCBI
2.	Molyneux EM, Rochford R, Griffin B, et al: Burkitt’s lymphoma. Lancet. 379:1234–1244. 2012.
3.	Akbayram S, Doğan M, Akgün C, et al: Use of rituximab in three children with relapsed/refractory Burkitt lymphoma. Target Oncol. 5:291–294. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Alasaad T and Barr R: Successful treatment of multiply relapsed lymphoma with rituximab as a single agent. Pediatr Blood Cancer. 55:356–358. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Attarbaschi A, Dworzak M, Steiner M, et al: Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer. 44:70–76. 2005. View Article : Google Scholar
6.	Bay A, Dogan M, Acikgoz M and Oner AF: Rituximab in a child with relapsed Burkitt lymphoma. Pediatr Blood Cancer. 49:2182007. View Article : Google Scholar : PubMed/NCBI
7.	Culić S, Culić V, Armanda V, et al: Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatr Hematol Oncol. 20:339–344. 2003.PubMed/NCBI
8.	Meinhardt A, Burkhardt B, Zimmermann M, et al: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol. 28:3115–3121. 2010.PubMed/NCBI
9.	Corbacioglu S, Eber S, Gungor T, et al: Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol Oncol. 25:327–329. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Griffin TC, Weitzman S, Weinstein H, et al: A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 52:177–181. 2009.PubMed/NCBI
11.	Boyle EM and Morschhauser F: Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma. Curr Oncol Rep. 13:386–397. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Leget GA and Czuczman MS: Use of rituximab, the new FDA approved antibody. Curr Opin Oncol. 10:548–551. 1998. View Article : Google Scholar : PubMed/NCBI
13.	Song KW, Mollee P, Patterson B, et al: Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 119:125–127. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Quartier P, Brethon B, Philippet P, et al: Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 358:1511–1513. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Zecca M, Nobili B, Ramenghi U, et al: Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 101:3857–3861. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Campo E, Swerdlow SH, Harris NL, et al: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Bhagavathi S and Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med. 132:1830–1834. 2008.PubMed/NCBI
18.	Abla O and Weitzman S: Primary central nervous system lymphoma in children. Neurosurg Focus. 21:E82006. View Article : Google Scholar : PubMed/NCBI
19.	Kawano N, Ochiai H, Yoshida S, et al: Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. Int J Clin Oncol. 17:336–340. 2012. View Article : Google Scholar : PubMed/NCBI